Related Experiment Video

Updated: Jan 22, 2026

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression
12:42

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Published on: August 28, 2012

15.6K

MUS81 Inhibition Increases the Sensitivity to Therapy Effect in Epithelial Ovarian Cancer via Regulating CyclinB

Ailing Zhong1, Hui Zheng1, Hongqin Zhang1

  • 1Department of Clinical Laboratory, Fudan University, Shanghai Cancer Center, Shanghai, China.

Journal of Cancer
|July 2, 2019
PubMed

Insights

Inhibiting the DNA repair enzyme MUS81 activates cell-cycle pathways and sensitizes ovarian cancer cells to treatments like X-ray and Olaparib, suggesting MUS81 as a potential therapeutic target.

Area of Science:

  • Molecular Biology
  • Genetics
  • Cancer Research

Background:

  • MUS81 is a crucial endonuclease in DNA double-strand break repair via homologous recombination (HR).
  • Structure-specific endonucleases (SSEs) are vital for DNA replication, repair, and transcription, requiring precise control for genome stability.
  • Previous studies indicated a correlation between MUS81 and CyclinB expression.

Purpose of the Study:

  • To investigate the role of MUS81 in ovarian cancer.
  • To determine if inhibiting MUS81 affects DNA damage repair pathways and chemosensitivity.
  • To evaluate MUS81 as a potential therapeutic target for epithelial ovarian cancer (EOC).

Main Methods:

  • Generated MUS81-downregulated ovarian cancer cells using lentivirus-mediated RNA interference (RNAi).
  • Analyzed the activation of CHK1 and CyclinB signaling pathways.
  • Assessed the sensitivity of these cells to X-ray and Olaparib treatment in vitro and in vivo.

Main Results:

  • Downregulation of MUS81 activated the CHK1 and CyclinB signaling pathways.
  • MUS81 inhibition sensitized ovarian cancer cells to both X-ray and Olaparib treatments.
  • These effects were observed in both in vitro and in vivo models.

Conclusions:

  • MUS81 inhibition represents a promising strategy to enhance the efficacy of existing cancer therapies.
  • Targeting MUS81 could be a viable therapeutic approach for epithelial ovarian cancer (EOC).
  • Further research into MUS81's role in DNA repair and cancer progression is warranted.
Keywords:
CyclinBDNA damage repairEOCMUS81Olaparib

More Related Videos

Methods to Inhibit Bacterial Pyomelanin Production and Determine the Corresponding Increase in Sensitivity to Oxidative Stress11:00

Methods to Inhibit Bacterial Pyomelanin Production and Determine the Corresponding Increase in Sensitivity to Oxidative Stress

Published on: August 31, 2015

8.7K
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses10:35

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

18.8K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.9K
Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
56.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.7K
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.5K
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.7K
GTPases and their Regulation02:14

GTPases and their Regulation

Guanine nucleotide-binding proteins (G-proteins), also known as GTPases, are a superfamily of proteins that regulate many cellular processes, such as cell signaling, vesicular transport, and the regulation of cell shape and motility. Mutation or dysfunction of these proteins can lead to disease. There are around 40,000 known G-proteins that can broadly be classified into two groups ‒  small G-proteins consisting of a single domain and large multi-domain G-proteins.
Large G-proteins,...
9.8K